Summary:
- The U.S. Food and Drug Administration (FDA) has approved Lantheus' new drug, Pylarify (piflufolastat F 18), for the detection of prostate cancer.
- Pylarify is a radioactive diagnostic agent that helps doctors locate and identify prostate cancer in patients using a specialized imaging technique called positron emission tomography (PET) scanning.
- This new drug approval provides an important new tool for healthcare providers to diagnose and manage prostate cancer, which is one of the most common types of cancer in men.